Vivolux widens its network of expertise.

The Vivolux board members and managers possess significant expertise within drug development, pharmacy, clinical pharmacology, clinical oncology, regulatory affairs, and business strategy. Professor Stig Linder's decision to become a share holder and board member means that the company can benefit from his vast experience in experimental oncology and have access to unique methods for studying apoptosis in spheres of human cancer cells. Bengt Ågerup's decision to invest in and become a member of the board of Vivolux means that the company has acquired further business expertise and financial resources to complete the preclinical development for our patented substances and move on to clinical trials. Vivolux is planning to conduct future development work from Uppsala and will therefore move from its present domicile in Gothenburg.